DBV Technologies (DBVT) EBITDA Margin (2020 - 2026)
DBV Technologies (DBVT) reported EBITDA Margin of 5777.78% for Q1 2026, down 249028.0% year-over-year from N/an in Q1 2025, and up 17.33% quarter-over-quarter from 6988.99% in Q4 2025.
DBV Technologies (DBVT) EBITDA Margin (2020 - 2026) Analysis & Trends
DBV Technologies (DBVT) has 7 years of EBITDA Margin data on file, last reported at 5777.78% in Q1 2026.
- EBITDA Margin for Q1 2026 came in at 5777.78%, down 249028.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 2868.65% (up 34376.0% YoY), and the FY2025 annual result was 2487.31%, up 35482.0% from the prior year.
- EBITDA Margin climbed to 5777.78% in Q1 2026 per DBVT's latest filing, from 6988.99% in the prior quarter.
- Over five years, EBITDA Margin peaked at 1451.0% in Q4 2022 and troughed at 6988.99% in Q4 2025.
- A 5-year average of 2256.32% and a median of 2162.69% in 2024 frame the typical range for EBITDA Margin.
- The sharpest annual moves came in 2022 and 2024: EBITDA Margin jumped 200489 bps in 2022, then tumbled 519655 bps in 2024.
- A 5-year view of EBITDA Margin shows it stood at 1451.0% in 2022, then sank by 104 bps to 55.7% in 2023, then tumbled by 9330 bps to 5252.25% in 2024, then tumbled by 33 bps to 6988.99% in 2025, then advanced by 17 bps to 5777.78% in 2026.
- Business Quant data shows DBVT's EBITDA Margin at 5777.78% in Q1 2026, 6988.99% in Q4 2025, and 1225.78% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -6.43% |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | DBV Technologies | 6.63 Bn | 6.41 Bn | -3.90 Mn | -5,777.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5,777.78% |
| Dec 31, 2025 | -6,988.99% |
| Sep 30, 2025 | -1,225.78% |
| Jun 30, 2025 | -2,378.23% |
| Mar 31, 2025 | -3,287.50% |
| Dec 31, 2024 | -5,252.25% |
| Sep 30, 2024 | -2,486.75% |
| Jun 30, 2024 | -2,932.90% |
| Mar 31, 2024 | -2,162.69% |
| Dec 31, 2023 | -55.70% |
| Sep 30, 2023 | -870.95% |
| Jun 30, 2023 | -1,069.71% |
| Mar 31, 2023 | -773.79% |
| Dec 31, 2022 | 1,451.00% |
| Sep 30, 2022 | -1,575.31% |
| Jun 30, 2022 | -2,238.98% |
| Mar 31, 2022 | -731.15% |
| Dec 31, 2021 | -553.89% |
| Sep 30, 2021 | -2,096.22% |
| Jun 30, 2021 | -1,869.49% |